Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics
Metadatos
Afficher la notice complèteAuteur
Martín Blázquez, Ariadna; Jiménez Luna, Cristina; Díaz, Caridad; Martínez-Galán, Joaquina; Prados Salazar, José Carlos; Vicente, Francisca; Melguizo Alonso, Consolación; Genilloud Rodríguez, Olga; Pérez del Palacio, José; Caba Pérez, OctavioEditorial
MDPI
Materia
Metabolomics Pancreatic ductal adenocarcinoma Reverse-phase liquid chromatography Biomarker Diagnosis
Date
2020-04Referencia bibliográfica
Martín-Blázquez, A., Jiménez-Luna, C., Díaz, C., Martínez-Galán, J., Prados, J., Vicente, F., ... & Caba, O. (2020). Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. Cancers, 12(4), 1002. [doi:10.3390/cancers12041002]
Patrocinador
This research was funded by JUNTA DE ANDALUCIA, grant number PIN-0474-2016 and PC-0549-2017 and INSTITUTO DE SALUD CARLOS III (FEDER), grant number DTS17/00081.Résumé
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers,
with a 5-year survival rate of less than 5%. In fact, complete surgical resection remains the only
curative treatment. However, fewer than 20% of patients are candidates for surgery at the time
of presentation. Hence, there is a critical need to identify diagnostic biomarkers with potential
clinical utility in this pathology. In this context, metabolomics could be a powerful tool to search
for new robust biomarkers. Comparative metabolomic profiling was performed in serum samples
from 59 unresectable PDAC patients and 60 healthy controls. Samples were analyzed by using an
untargeted metabolomics workflow based on liquid chromatography, coupled to high-resolution mass
spectrometry in positive and negative electrospray ionization modes. Univariate and multivariate
analysis allowed the identification of potential candidates that were significantly altered in PDAC
patients. A panel of nine candidates yielded excellent diagnostic capacities. Pathway analysis revealed
four altered pathways in our patients. This study shows the potential of liquid chromatography
coupled to high-resolution mass spectrometry as a diagnostic tool for PDAC. Furthermore, it identified
novel robust biomarkers with excellent diagnostic capacities.